{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011486","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.650479+00:00","generated_at":"2026-05-31T11:09:58.777493+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Virios Q2 net loss $1.0M; Long-COVID Phase 2a data expected Oct 2024","bullets":["Net loss $1.0M ($0.05/sh) vs $1.4M ($0.08/sh) in Q2 2023; revenue was $0.","Cash $3.0M at June 30, 2024; expects runway into Q1 2025 after $1.7M public offering.","Enrollment completed in Long-COVID Phase 2a (valacyclovir/celecoxib vs placebo); top-line data October 2024.","R&D expense fell to $0.3M from $0.6M; G&A fell to $0.7M from $0.9M, both YoY.","Blinded safety analysis shows no serious adverse events; study drug well tolerated to date."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011486","json":"https://secwatch.observer/filing/0001558370-24-011486.json","markdown":"https://secwatch.observer/filing/0001558370-24-011486.md","text":"https://secwatch.observer/filing/0001558370-24-011486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024011486/0001558370-24-011486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000155837024011486/viri-20240808x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:09:58.777493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}